Literature DB >> 17719079

MTHFR C677T mutation in central retinal vein occlusion: a case-control study in Chinese population.

Wei Gao1, Yu-Sheng Wang, Peng Zhang, Hai-Yan Wang.   

Abstract

Our previous study found that hyperhomocysteinemia was strongly associated with central retinal vein occlusion (CRVO) in the Chinese population. The aim of this study is to determine whether MTHFR C677T mutation is an independent risk factor for CRVO in the Chinese population. A matched case-control study was conducted between July 2004 and May 2005. The study cohort consisted of 64 individuals that had been diagnosed with CRVO and 64 healthy controls (matched for age, gender, hypertension, smoking, and drinking habits). None of the cases or controls had a history of diabetes, glaucoma, medication or any other vascular events that might influence plasma homocysteine levels. A cross-sectional analysis among the 64 cases was performed to compare the prevalence of MTHFR C677T mutation among subjects with and without ischemia and subjects aged above 45 and below 45 years. MTHFR C677T mutation was determined by the template-directed dye-terminator incorporation with fluorescence polarization (TDI-FP) method. The result showed that the prevalence of the MTHFR 677 TT genotype did not significantly differ between patients and controls. However, 10 (34.5%) MTHFR C677 TT genotype was found in the ischemic group but only 4 (14.3%) in the nonischemic group (p=0.026). And we found that 6 MTHFR C677 TT genotype patients who have hyperhomocysteinemia in the ischemic group but only 2 in the nonischemic group (p=0.016). It suggests that MTHFR C677T mutation is associated with hyperhomocysteinemia in the ischemic CRVO in the Chinese population. It may contribute to hyperhomocysteinemia and associate with the development of CRVO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719079     DOI: 10.1016/j.thromres.2007.05.026

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality.

Authors:  Jane Zea-Chin Kuo; Chi-Chun Lai; Frank Shih-Chang Ong; Chia-Pang Shih; Ling Yeung; Tun-Lu Chen; Kuan-Jen Chen; Wei-Chi Wu
Journal:  Retina       Date:  2010-03       Impact factor: 4.256

2.  Hyperhomocysteinemia, a biochemical tool for differentiating ischemic and nonischemic central retinal vein occlusion during the early acute phase.

Authors:  Kapil Deb Lahiri; Somnath Mukherjee; Sambuddha Ghosh; Suman Mukherjee; Jayanta Dutta; Himadri Datta; Harendra Nath Das
Journal:  Korean J Ophthalmol       Date:  2015-03-17

3.  Role of Hyperhomocysteinemia and Methylene Tetrahydrofolate Reductase C677T Polymorphism in Idiopathic Portal Vein Thrombosis.

Authors:  Habib Ghaznavi; Zahra Soheili; Shahram Samiei; Mohammad Soleiman Soltanpour
Journal:  Vasc Specialist Int       Date:  2016-03-31

4.  Preservation of retinal structure and function after cilioretinal artery occlusion: a case report.

Authors:  Craig J Brown
Journal:  Int Med Case Rep J       Date:  2016-02-11

5.  Meta-analysis of the relationship between methylenetetrahydrofolate reductase C677T and A1298C polymorphism and venous thromboembolism in the Caucasian and Asian.

Authors:  Miao Gao; Na Feng; Meixia Zhang; Xinyu Ti; Xiuping Zuo
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

6.  Effects of Common Thrombophilia Factor Mutations in Central Retinal Vein Occlusion.

Authors:  Muhammer Ozgur Cevik; Sadik Gorkem Cevik
Journal:  Beyoglu Eye J       Date:  2019-04-10

7.  Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study.

Authors:  Song Zhang; Tianxun Wang; Huaiqi Wang; Jianping Tang; Ailin Hou; Xiaoling Yan; Baozhong Yu; Shuangming Ran; Min Luo; Ying Tang; Ruohan Yang; Dongsheng Song; Hanjun He
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.